MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

CareDx Inc

Open

SectorGezondheidszorg

20.22 -1.7

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.81

Max

20.58

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.477

87.826

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+27.76% upside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

268M

1.1B

Vorige openingsprijs

21.92

Vorige sluitingsprijs

20.22

Nieuwssentiment

By Acuity

43%

57%

155 / 370 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jan 2026, 23:54 UTC

Marktinformatie

CBA Could Underperform Again in 2026 -- Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

12 jan 2026, 23:43 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 jan 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 jan 2026, 21:56 UTC

Marktinformatie

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 jan 2026, 20:54 UTC

Winsten

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 jan 2026, 20:48 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 jan 2026, 20:33 UTC

Marktinformatie

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 jan 2026, 19:39 UTC

Marktinformatie

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 19:33 UTC

Marktinformatie

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 jan 2026, 19:24 UTC

Acquisities, Fusies, Overnames

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 jan 2026, 19:22 UTC

Acquisities, Fusies, Overnames

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 jan 2026, 18:21 UTC

Acquisities, Fusies, Overnames

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 jan 2026, 18:20 UTC

Acquisities, Fusies, Overnames

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 jan 2026, 18:19 UTC

Marktinformatie

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 jan 2026, 18:16 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 jan 2026, 18:01 UTC

Acquisities, Fusies, Overnames

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 jan 2026, 18:00 UTC

Marktinformatie

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

27.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD  27.76%

Hoogste 26 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

155 / 370 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat